Jasper Therapeutics (JSPR) Net Income (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Net Income of -$16.0 million for Q4 2025, up 35.08% year-over-year from -$11.8 million in Q4 2024, and up 15.27% quarter-over-quarter from -$18.9 million in Q3 2025.
Jasper Therapeutics (JSPR) Net Income (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Net Income history runs 6 years deep, the most recent figure standing at -$16.0 million for Q4 2025.
- In Q4 2025, Net Income rose 35.08% year-over-year to -$16.0 million; the TTM figure through Dec 2025 stood at -$85.1 million (down 11.17% YoY), while the FY2025 annual figure was -$84.0 million, down 7.94% from the prior year.
- Net Income for Q4 2025 stood at -$16.0 million, up from -$18.9 million in the prior quarter.
- The five-year high for Net Income was $5.5 million in Q1 2021, with the low at -$28.9 million in Q2 2025.
- The 5-year median for Net Income is -$15.5 million (2024), against an average of -$15.4 million.
- Peak annual rise in Net Income reached 284.79% in 2021, while the deepest fall reached 4536.03% in 2021.
- Jasper Therapeutics' Net Income stood at -$11.9 million in 2021, then decreased by 19.41% to -$14.2 million in 2022, then slipped by 17.77% to -$16.8 million in 2023, then slumped by 46.88% to -$24.6 million in 2024, then surged by 35.08% to -$16.0 million in 2025.
- Business Quant data shows JSPR's Net Income at -$16.0 million in Q4 2025, -$18.9 million in Q3 2025, and -$28.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 81.49 Mn |
| 10 | Jasper Therapeutics | 19.97 Mn | 19.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.00 Mn |
| Sep 30, 2025 | -18.88 Mn |
| Jun 30, 2025 | -28.89 Mn |
| Mar 31, 2025 | -21.32 Mn |
| Dec 31, 2024 | -24.64 Mn |
| Sep 30, 2024 | -22.47 Mn |
| Jun 30, 2024 | -15.02 Mn |
| Mar 31, 2024 | -14.40 Mn |
| Dec 31, 2023 | -16.78 Mn |
| Sep 30, 2023 | -21.29 Mn |
| Jun 30, 2023 | -17.58 Mn |
| Mar 31, 2023 | -13.13 Mn |
| Dec 31, 2022 | -14.25 Mn |
| Sep 30, 2022 | -13.19 Mn |
| Jun 30, 2022 | -11.97 Mn |
| Mar 31, 2022 | -17.74 Mn |
| Dec 31, 2021 | -11.93 Mn |
| Sep 30, 2021 | -10.08 Mn |
| Jun 30, 2021 | -3.57 Mn |
| Mar 31, 2021 | 5.50 Mn |